Handok

Things may be looking up in the US for adalimumab biosimilars, but Coherus BioSciences, Inc. 's decision to divest Yusimry (adalimumab-aqvh) saw analysts raise questions on the wider prospects for ri

Things may be looking up in the US for adalimumab biosimilars, but Coherus BioSciences, Inc. 's decision to divest Yusimry (adalimumab-aqvh) saw analysts raise questions on the wider prospects for ri

Biocon has notched up yet another partnership deal on liraglutide, striking an agreement with Korean firm Handok for its generic version of the chronic weight management treatment. Underlining the

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Ono Calls On PRISM For Oncology Di